The biomedical research complex has been estimated to consume almost a quarter of a trillion US dollars every year. Unfortunately, evidence suggests that a high proportion of this sum is avoidably wasted. In 2014, The Lancet published a series of fi ve reviews showing how dividends from the investment in research might be increased from the relevance and priorities of the questions being asked, to how the research is designed, conducted, and reported. 17 recommendations were addressed to fi ve main stakeholders-funders, regulators, journals, academic institutions, and researchers. This Review provides some initial observations on the possible eff ects of the Series, which seems to have provoked several important discussions and is on the agendas of several key players. Some examples of individual initiatives show ways to reduce waste and increase value in biomedical research. This momentum will probably move strongly across stakeholder groups, if collaborative relationships evolve between key players; further important work is needed to increase research value. A forthcoming meeting in Edinburgh, UK, will provide an initial forum within which to foster the collaboration needed.
Introduction
More than 30 years ago, the adverse clinical consequences of biased under-reporting of research were clearly documented 1 and non-publication of research remains hugely problematic. [2] [3] [4] [5] Non-publication is bad value for funders, who could double research output by ensuring all the funded studies are published, and this situation puts patients and clinicians at a substantial disadvantage in making informed decisions about health care. 6 Trial registration, supported by the International Committee of Medical Journal Editors (ICMJE), 7 has helped to address this problem 8, 9 although this solution is clearly not a panacea. 10, 11 Other related initiatives, such as the Alltrials initiative and the Institute of Medicine's report on data sharing 12 are working to ensure that the results of all trials are reported and that their data are made available.
Chalmers and Glasziou 13 estimated in 2009 that 85% of research funding was being avoidably wasted across the entire biomedical research range (eg, clinical, health services, and basic science). Evidence of the extent and avoidability of waste in research production at each stage of the authors' four stage model has grown, and has confi rmed imbalanced research question selection, 14 poor study design 15, 16 and execution, non-publication, 17 and poor reporting 18 and some have suggested that a more fundamental reassessment is needed in how research priorities are developed and pursued. 19, 20 In addition to 228 citations as of Sept 11, 2015 , the 2009 paper 13 led National Institute of Health Research (NIHR) in England to establish a working group to monitor and plan actions, with regular meetings and an annual closed conference. The NIHR's Adding Value in Research programme had an additional stage (fi gure 1) aiming to ensure that NIHR funded research: addresses questions relevant to clinicians, patients, and the public; uses appropriate design and methods; is delivered effi ciently; results in accessible full publication; and produces unbiased and useable reports. NIHR developed a quality improvement method 21 for these fi ve stages to identify common themes and examples of good practice across their programmes. For example, since 2013, NIHR has required applicants for support of new primary research to reference an existing systematic review "as well as including reference to any relevant literature published subsequent to that systematic review" or when no such systematic review exists, applicants should review the relevant evidence (with a method that systematically identifi es, critically appraises, and combines the evidence), which "must also include reference to relevant on-going studies, eg, from trial registries". 22 In 2014 The Lancet published a Series ("Increasing value: reducing waste") [23] [24] [25] [26] [27] extending the 2009 analysis from 4 to 50 journal pages, with more than 40 authors focused on the fi ve NIHR stages. As the Commissioning Editors noted: "Our belief is that research funders, scientifi c societies, school and university teachers, professional medical associations, and scientifi c publishers (and their editors) can use this Series as an opportunity to examine more forensically why they are doing what they do…and whether they are getting the most value for the time and money invested in science." 28 The Series, and an accompanying symposium, 29 provided a voluminous body of evidence for the issues in biomedical research, along with 17 recommendations (table 1) to help to increase value, covering funders, regulators, journals, academic institutions, and re searchers. These issues include (although they are not limited to) whether planned research met the needs of end users. [30] [31] [32] Initial media attention included coverage by several newspapers including the leading German paper, Der Spiegel, 33 although almost no response has been made from German researchers or organisations (Antes G, German Cochrane Centre, personal communication). Several research funders responded through meetings, working parties, and some changes of processes. In the year since their publication, the fi ve articles have been downloaded 46 596 times from The Lancet and ScienceDirect websites. The fi ve Series papers have already been cited 113 times (Scopus); were all in the top 5% of all articles indexed by Scopus; and their alternative metric scores (used to measure social media) all ranked more than the 98th percentile (of more than 3 million articles scored) including 589 tweets (about 20% of which were by health-care professionals).
This follow-up Review off ers an overview of the initial stimulus of the Series. Before the assessment, a protocol was developed outlining the key players and the methods of our investigation, including sampling frames (panel 1). The primary focus was to assess what funders, regulators, journals, academic institutions, and researchers are doing, and plan to do, to address waste in biomedical research.
Funders
A few funders have already responded to the Series. In May, 2014, the French Institute of Health and Medical Research, Institut National de la Santé et de la Recherche Médicale (INSERM), in conjunction with the Enhancing the Quality and Transparency of Health Research (EQUATOR) network, organised a 1-day conference in Paris on "Improving reporting to decrease the waste of research" with the director of the Wellcome Trust and NIHR's Health Technology Assessment programme among the speakers (video of all sessions is available on the EQUATOR website). 37 The Series was included in discussions of INSERM's strategic plan for 2016-20, and was presented at the annual meeting of INSERM team leaders. 38 In Australia, the National Health and Medical Research Council set up a working party to review all the recommendations in the Series (Ghersi D. National Health and Medical Research Council, personal communication), updating and modifying their pro cedures, and featured an opening session entitled Adding value, reducing waste at their 2014 annual scientifi c meeting. 39 The Series was discussed at the Heads of International Research Organizations group's meeting in 2014 in Ottawa, Canada.
We are also heartened that concern about poor replicability and quality of animal and other preclinical research 40 has prompted some infl uential organisations to draw attention to and address these concerns. For example, a meeting on reproducibility and reliability of biomedical research was convened jointly by the UK Academy of Medical Sciences, the UK Medical Research Council, the Wellcome Trust, and the Biotechnology and Biological Sciences Research Council. The National Centre for the Replacement, Refi nement and Reduction of Animals in Research has supported three international meetings (in Nijmegen, Netherlands; Edinburgh, UK; and Washington DC, USA) about systematic reviews of animal research, and in 2015 held an international meeting in London, UK on biased under-reporting of animal research, 41 bringing together several relevant groups targeted in the Series. Some important papers drawing attention to issues with the reproducibility of research have also been published. [42] [43] [44] Whether or not the Lancet Series had any role in these initiatives, they are very welcome.
The investigation of the funders' websites (panel 1) suggests that most funders are not explicit about many of the key issues of research policies, which made this assessment challenging. The NIHR's website had several innovative and exemplary features, such as the requirements for systematic reviews before the initiation of additional primary studies, active monitoring of in progress studies, and NIHR's own journals. For other funders, the picture was more mixed than NIHR's website (table 2) . [45] [46] [47] Most organisations required trial registration, but few needed systematic reviews before beginning additional primary studies, or mentioned reporting guidelines, such as Consolidated Standards of Reporting Trials, or the EQUATOR network. NIHR is an exception, compared with the other organisations studied, in that systematic reviews are needed for any research project submissions (table 1) . Only two of these funders had a substantial targeted research scheme that 
To further investigate how funders address the issues and recommendations in the Series, we searched the websites of six funders. These were selected purposively to gauge activities of some large funders and those in proximity to the authors. We assessed documents such as instructions to funding applicants then checked our findings with the funder.
Journals
To further explore how journals are dealing with the seven recommendations from the Series most relevant to them, we assessed the websites of the 120 core clinical journals included in MEDLINE's Abridged Index Medicus, 34 particularly their instructions to authors. Journal websites had similar responses across most of the questions; about half of them had information we were seeking (fi gure 1). We also interviewed two editors from general medical journals (BMJ, The Lancet), an editor from a specialty journal (Archives of Physical Medicine and Rehabilitation), an editor from a predominantly methods-based journal (Journal of Clinical Epidemiology), and an editorial director (PLoS journals) with a structured interview guide of ten questions.
Academic institutions
We assessed the extent to which academic institutions have policies to make study materials publically available, a recommendation from the Series. Deans and directors of research of the medical schools of the top 100 universities from the Times Higher Education 35 World University Rankings 2013-14 (ordered by clinical, preclinical, and health) were invited to participate in a fi ve-question email survey.
Researchers
To identify the extent of support among researchers for the recommendations in the Series, and the perceived barriers to adherence, we did a qualitative online survey as we did not aim to have a representative sample but to emphasise diff erent perceptions of clinical and preclinical researchers. We surveyed basic scientists (n=59) and clinical researchers (n=70) who published in high impact factor journals or were listed as highly infl uential researchers.
Organization's International Clinical Trials Registry
Platform and PROSPERO; table 1). For example, a review 48 of 75 randomised trial protocols funded at NIHR's Health Technology Assessment programme, Southampton, UK, showed these protocols often did not provide adequate information about allocation sequence generation (13% missing) and concealment (19% missing): important characteristics of well conducted randomised trials. Funders could also consider stronger policies than at present to support (guidance, education, and infra structure) and enforce (incentives and penalties) publication of all research, open access, and data sharing.
Regulators
Regulators can help with this goal by not providing ethics approval of protocols that are scientifi cally poor, which would mean that these protocols are also ethically inadequate. For example, the guidance for researchers issued by the newly established Health Research Authority (HRA) 49 in the UK now states: "Any project should build on a review of current knowledge. Replication to check the validity of previous research is justifi ed, but unnecessary duplication is unethical."
Conversely, research regulators can reduce waste resulting from ineffi ciencies in research regulation. Some of these ineffi ciencies result from hyper-regulation of low risk non-interventionist research, such as many descriptive surveys. After a report 50 from the Academy of Medical Sciences, UK, HRA is now addressing this issue. As a result, proportionate measures for assessments of research proposals have been introduced that take into account the plausible risks associated with the research proposals being considered.
Some research regulators have also taken steps to reduce the problem of biased under-reporting of research (table 1) . In the UK, a favourable ethics opinion for proposed clinical trials will not be granted unless the proposed trial has been registered publicly. 51 After pressure from the Alltrials campaign, the European Medicines Agency has now committed to make available all clinical study reports of research leading to marketing licences for new drugs (table 1) . 52 
Journals
In view of the fact that more than half of the reports of clinical trials do not set their results in the context of the totality of evidence, 27 journals have much work to do to improve this situation. Journals can progress by providing specifi c guidance on their websites about this crucial feature and by providing similar guidance to peer reviewers. In response to the Series, The Lancet strengthened the journal's requirement to put research into context (table 1) . 53 From the beginning of this year, all research papers submitted to any journal in The Lancet family must include a research in context panel. The Editors expressed their "hope that increasing the prominence of putting research into context in the submission and publication stages will help researchers, institutions, and funders to make decisions earlier in the process on which research questions to address and fund". Other journals have made similar eff orts, such as the addition of panels asking authors what this paper adds. However, something more explicit, such as the research in context panel, might be more helpful. To complement these initiatives, the Transparency and Openness Publications committee has proposed journal guidance to increase author transparency, openness, and reproducibility. 54 On the basis of our interviews with journals editors (panels 1, 2), the Lancet Series has been an impetus for consideration and change in some editors. The papers have been discussed internally during in-house editorial meetings, at an editorial board retreat for a journal, and is on the agenda for discussions with other editorial boards. The Series has also been on the agenda of infl uential editorial groups, such as ICMJE, and other continuing initiatives, such as the Institute of Medicine's report on data sharing. 12 Some journals have already acted in response to the Series. For example, PLoS Medicine commissioned an editorial on how open access can reduce waste. 55 Other concurrent initiatives focused on the reduction of research waste, not directly attributable to the Series, are also underway. For example, a large group of Yes for clinical trials, the state of the research specialty and evidence is to be included in the proposals; for clinical trials, the structured search for evidence has to be described or systematic reviews to be referenced; the comprehensive description of the existing evidence is a key reviewing criterion; systematic reviews can be funded in the individual grants programmes
Yes for clinical trials only
Suggestions and examples for researchers are available for the reuse of research data; DFG strongly encourages researchers to have strategies to reuse data "In order to enhance the long-term archiving and curation of research data, the DFG funds projects that seek to achieve an effi cient reuse of research data" but this inclusion is not compulsory All clinical trials funded after June 1, 2014, have to deposit the study protocol at the clinical trials registry before trial start but not for other study designs DFG is the self-governing organisation for science and research in Germany, serving science and the humanities; the main task of the DFG is to select and fi nance the best research projects on a competitive basis; projects by scientists and academics or by universities deal with topics from a particular discipline or from an interdisciplinary approach; in a multilayered decision making process, the proposal is assessed by voluntary reviewers exclusively according to scientifi c criteria and then assessed by chosen members of the review board, and the fi nal decision is made by the Grants Committee; as a result, DFG funding guarantees quality-based diff erentiation in the German research system; any eligible researcher can submit a funding proposal at any time and on any research topic; because the DFG does not specify a topic for proposals, but, instead, reacts to proposals on any topic, the organisation promotes research mainly in what is known as response mode, therefore complementing the agenda driven and programme oriented funding by the ministry of research and education (BMBF) 56 This policy is likely to introduce a strong incentive to prospective authors across this content area to use reporting guidelines. Other specialties, such as surgery, are starting to implement similar strong guidance. 57 The results of investigating the journals' websites (panels 1, 2) show the wide variability of information contained on journal websites and the language used across journals (fi gure 2). This variability will probably confuse prospective authors, particularly those early on in their research careers and those whose fi rst language is not English. Although journals want to maintain their uniqueness, and emphasise particular issues that are important to them, some items, perhaps particularly those related to the recommendations in the Series, might be considered as core information and unambiguous language could be included across all journal websites. This approach might help to improve matters for journals, prospective authors, and readers.
One immediate goal could be for every journal to explicitly support the use of reporting guidelines (table 1) . The evidence suggests that guideline use is associated with increases in the completeness of reporting of clinical trials. 58 Roughly half of the websites we investigated mentioned reporting guidelines, which is a similar proportion to that reported by Hirst (table 1) .
Journals can also add value to their websites by explicitly asking authors to provide more information about their methods, particularly the interventions used or details of participants. For example, 30 (12%) reports from a sample of 255 cancer trials provided suffi cient information about the interventions studied 60 to allow clinicians to use the results in practice. 61 Across the ten questions used to assess the websites, the results did not vary substantially by journal impact factor (<5 vs ≥5).
Academic institutions
We are aware of very little explicit attention by academic institutions to the Lancet Series. An exception has been in Iran, where a group of academics are running a series of workshops on the Lancet series. Two workshops on "Biomedical research: increasing value, reducing waste" were run in Based on our email survey (panel 1), we received complete responses from only 26 of the 100 invited universities. We noted that most of these schools (n=20) have a policy to register clinical trials in a publicly accessible trial registry and to make full study reports available (n=19), but such policies are rare for protocols (n=5), analytical algorithms (n=5), and raw data (n=5). Two of 26 universities did not have an institutional policy for any of these fi ve elements (table 1) .
Only fi ve medical schools reported having a policy to make all study protocols publicly available. At Duke University in the USA, for example, "all approved study protocols are available through the School of Medicine's electronic IRB [Institutional Review Board] pathway", but such a repository for study protocols seems rare in other universities. By contrast, prospective registration of clinical trials in a publicly accessible trial register is enforced by almost all institutions we surveyed. Although registration seems common in highly respected research institutions, the extent to which this policy is adhered to in less prestigious academic institutions is unclear. Trial registration has been required by the ICMJE since 2005, 7 and some governmental institutions, such as the US Food and Drug Administration (FDA), require registration of all clinical trials. 7 Despite these policies, only about half of all published trials are currently being registered. 62 At Duke University, "registration at ClinicalTrials.gov is required before IRB approval, and registration record completion is required before IRB close-out". These examples emphasise the importance of regulation to help to maximise best research practice.
Up to half of all initiated clinical trials are unpublished. 63 The FDA requires posting of clinical trial results in ClinicalTrials.gov within a year after study completion, but this posting is done for less than a quarter of trials that are within the FDA's mandatory reporting rules, 64 possibly because of no enforcement. This situation shows the important role of universities in further enforcing the publication of all trial results. Most of the responding deans said they have a policy to make publicly available full publications of studies done at their institution (table 1) . The University of Sydney, Australia, is in the fi nal stages of establishing an open access policy that "will make publications available whenever copyright/ archiving policies allow through its external access repository, no later than 12 months after the date of publication. Where access to the full text of collected scholarly works is not permitted by the publisher, publication of metadata and a link to the published work will be made openly available". At the University of Groningen, Netherlands, "full publications are typically published in its fi nal version in the University Repository and thus largely publicly available". Policies to make raw data and analytical algorithms publicly available seem much rarer than clinical trial results, although individual universities show promising initiatives (table 1). The University of Sydney has a "research data registry and Electronic Lab Notebook platform, both of which enable the publication of metadata (ie, data about data; data that describes and gives information about other data) and data sets". The University states that "Researchers should make completed research data sets openly available for re-use by other researchers, unless this is prevented by the requirements of legislation or University policy, or ethical, contractual or confi dentially obligations. If open access is not possible due to legal or policy reasons, researchers should make metadata openly available."
Other universities have less explicit policies. Cambridge University, UK, for example, explicitly "encourages researchers to be as open as possible in discussing work with other researchers and with the public. Once results have been published, the University expects researchers to make available relevant data and materials to other researchers, on request". At the University of Bristol, UK, "researchers can make study protocols, raw data and analytical algorithms publicly available at the institutional data repository". Beyond the stated policies, no data are available for whether and how the universities monitor the implementation of any of these policies.
The slow uptake of some of the recommendations by academic institutions is unfortunate, since a large proportion of all biomedical research resources go to universities. 65 An explanation might be because university policies on these issues are rarely defi ned at a nationwide or even a global level, making coordination of policies diffi cult. This situation can be shown by the large diversity in the policies of the surveyed universities to make study materials publicly available.
Researchers
Motivated by the principle that initiation of research without a systematic review of already known evidence is unethical, unscientifi c, and wasteful, particularly when the research involves people or animals, three Scandinavian researchers 66 convened and inaugurated an international Evidence-Based Research Network at the end of 2014. This network will urge funders, regulators, researchers, academic institutions, and journals to implement the changes needed to promote evidence-based research. Initiatives such as Trial Forge, 67 and the Clinical Trials Transformation Initiative 68 aiming to improve trial undertaking, should also help researchers to maximise the effi ciencies in clinical trials (table 1) . To help to promote greater effi ciencies in the research process several US Governmental agencies have released regulations that streamline and simplify the conduct of research involving human beings. 69 Additionally, in May 2015, the PRECIS-2 was published to help researchers during the design phase of their studies. 70 Most researchers agreed that the Series was important to increase research value. However, basic scientists and clinical researchers had notably diff erent perceptions of the concept of waste in research. For example, some basic scientists disagreed with the concept and believed that waste was less important in their specialty (eg, " […] to state that 85% of research funding is wasted is an insult to current research eff orts"; "There is no […] waste in pure, basic science"). Some of these individuals were concerned by the risk of a negative eff ect of the Series on the societal view of the value of research, which could result in decreased funding. The reluctance of basic researchers to acknowledge waste in research in their specialty contrasts with the scarcity of reproducibility of basic and preclinical research. 5, 71 Most researchers endorsed the Series recommendations. Nevertheless, these individuals identifi ed some barriers to increasing of research value (table 3) .
Barriers to protocol registration and data sharing included the fear of inappropriate use of data, issues related to patient confi dentiality, the protection of original researchers' eff orts, and the risk of researchers having ideas stolen by others. Some individuals also thought that adherence to these recommendations could decrease researchers' autonomy and might be an obstacle to scientifi c discovery (eg, "In basic science, there is a great need for fl exibility to modify the protocol in response to the latest fi nding. Too rigorous control on the planning of experiments would simply kill the last nerve in basic research"; "Research is not a car factory").
A shortage of expertise and appropriate support were also important barriers to systematic reviews being done before plans of additional studies. Some researchers expressed some concern about the emergence of several quality constraints, adding many discrete tasks (eg, protocol registration, adherence to reporting guidelines, and data sharing) that would create a cumulative and discouraging burden for researchers (eg, "We can't overly restrain creative scientists with organizational rules without burdening their work"). In fact, although adherence to these recommendations should have a positive collective eff ect for patients and researchers, perhaps researchers should be rewarded for imple menting them. Finally, researchers identifi ed important structural factors associated with waste in research, such as the top-down funding system with an inappropriate identifi cation of priorities from funders rather than the bottom-up approach from researchers, a questionable peer-review and selection process, the ever-growing restrictions in research, and a reward system based on quantity of publications and journal impact factor rather than on research quality. These barriers should be taken into consideration and provide appropriate education, incentives, and support to improve researchers' compliance
Barriers identifi ed Facilitators
Perform a systematic review of all available evidence before planning a study Basic researchers: "The primary barrier is the vast amount of information that has to be surveyed combined with reduced time to linger and concentrate on a given project in university institutions in general." Additionally: "There is no such thing as all available evidence. What constitutes evidence for a particular study is integral part of the conceptualization of the study. Diff erent people have legitimately diff erent methods in using evidence. Too much evidence, some of which is just bad data, can be paralyzing and prevent innovation" Clinical researchers: "Very expensive and time consuming to do full systematic reviews and most researchers aren't good at it"
Funders to make a systematic review a condition for grant submission; funders and journals to collaborate on developing educational instruments for research in context; institutions to provide methodological and logistical support to researchers to do systematic reviews Systematically register study protocol at inception Develop appropriate repository for basic scientists; provide specifi c funding and logistical support to researchers to make these documents and data available; funders, institutions, and editors to reward researchers making the protocol, analysis plan, results, and raw data publicly available Make raw data publicly available Basic researchers: "...scarcity of suitable repositories and little funding to establish these" Clinical researchers: "...this would create many issues such as confi dentiality, which would need to be redacted and would waste time; probably reluctance to give access to such data exists because others could use them for their own purposes; and mass sharing of data could lead to inappropriate use, as the context of data collection and the objective of the study are necessary to understand their meaning"
Develop appropriate repository for basic scientists; provide specifi c funding and logistical support to researchers to make these data available; funders, institutions, and editors to reward researchers making the protocol, analysis plan, results, and raw data publicly available 
Looking to the future
The overall response to the 2014 Series might be summed up as some gratifying actions, but much more needs to be done to reduce research waste than at present. From a bibliometric and social media perspective, the Series has gained some traction, which is encouraging. Recognition of the problems described in the Series, and dialogue about the recommendations and possible ways to monitor progress are important fi rst steps. However, if researchers are to avoid the well known issue of not implementing research knowledge into practice, 72 scientists will need to use systematically planned knowledge translation strategies, including the use of theory-based strategies, 73 to aff ect research practice, programmes, and policies of groups such as funders, regulators, journals, academic institutions, and researchers. A good starting point might be to revisit the Series' recommendations and consider ways to monitor increased research value (table 1) .
Across funders, regulators, journals, academic institutions, and researchers our investigation has shown some innovation and leadership, and suggestions of potential change, all of which need to be harnessed and sustained. Historically, the stakeholders have their own venues to talk and act within, such as the ICMJE for editors and Heads of International Research Organizations for funders. However, we are unaware of any venue in which these groups collectively engage to discuss and exchange ideas, or promote better research practice than at present. The paradox is that the issues outlined in the Series are large and complex (eg, large systemic and cultural diff erences probably exist between groups, such as preclinical and clinical researchers, and health services and populations health researchers, in how much of an issue these groups perceive research waste to be or how they think waste should be reduced) and no one group is responsible for addressing these concerns. Research value might be optimised through more collaborative eff orts. An immediate venue to help to begin the dialogue is the forthcoming REduce Waste And Reward Diligence (REWARD, and EQUATOR conference in Edinburgh, UK, on Sept 28-30, 2015 . This collaboration was envisaged as an annual forum to monitor progress and exchange ideas for the improvement of the entire research system. The structure of the meeting has been set up to help to promote and harness collaboration between all of the sectorial groups and will specifi cally include a meeting of several networks interested in improvement of at least one of NIHR's fi ve stages.
All fi ve targeted groups have a part to play in increasing research value. Some argue that the most eff ective strategy for maximising research value might be through the leadership of funders and regulators. Funders can use funding policies to support recommendations in the Series and provide guidance to researchers on how to minimise waste. For example, the National Institutes of Health off ers training in Responsible Conduct of Research, 74 an emphasis shown in initiatives of some professional bodies, such as the American Psychological Association. 75 Funders can use strong fi nancial incentives such as withholding a proportion of grant funding for research that has not yet been made publicly available to encourage public distribution. Regulators also have the authority to enforce change in keeping with the Series recommendations. 52 Additionally, research ethics boards, for example, could have a greater role than at present in checking that research in an area has been shown to be needed and helping to ensure that all relevant studies are appropriately registered (table 1) .
Some argue that academic institutions are ideally placed to lead the movement to enhance research value. These universities are training subsequent generations of researchers, some of whom migrate to other places of employment, such as journals, funders, and academic institutions. For example, perhaps universities could employ a new professional publications offi cer to help researchers, their staff , and trainees to adhere to policies of funders and journals, such as registering their studies at inception and using reporting guidelines to report their research. 76 Other innovations could also be integrated into the role of publications offi cers, including helping researchers in the development of research protocols. 77 Another strategy that might be considered is setting adherence targets for each of the Series' 17 recom mendations and monitoring progress towards achieving the targets. Would it be unreasonable to consider annual increases in research value, say by 10% over the next decade? For example, a 2012 survey 59 of journals' instructions to peer reviewers showed that reference to or recommendations to use of reporting guidelines during peer review was rare (19 [16%] of 116 journals assessed). Positive annual incremental change could be an improvement of at least 10% from 2012 in guidance to peer reviewers in the 116 journals initially surveyed. More active dissemination of recommendations, in keeping with the Series recom mendations, might include journal organisations, such as ICMJE and the World Association of Medical Editors, promoting use of reporting guidelines by peer reviewers and authors. This distribution might constitute part of a instrument for groups aff ected by reporting research. More generally, increases in research value can cut across stakeholders and dimensions of research (table 1) . These issues along with a general discussion about infrastructure needed to enable and monitor change in research value, and ways to fund it, will be discussed in the REWARD/EQUATOR meeting, which is planned as a series of meetings to bring funders, editors, and research organisations together with groups working on methods to reduce research waste. Perhaps it is also time to reconsider how the entire research awards system works? This system has been in place for a long time and the state of biomedical research suggests a diff erent set of metrics and currencies might be needed to increase the value of research investment (table 1) . During the waste launch symposium, 29 some argued that the reward system is conservative and closed to new ideas. Alternative systems could be discussed, piloted, assessed, and implemented if they improve research value. 78, 79 The need for a change in the research reward system is also something that could be discussed at the REWARD/EQUATOR meeting.
Our initial observations are based, in part, on assessing websites, which were often diffi cult to navigate. Similarly, we could have missed information or some of the content might have been modifi ed since our investigation. For example, on some journal websites instructions to authors are modifi ed at the beginning of the calendar year. The survey response rates were also lower than we would have liked, therefore needing more cautious interpretation.
This overview is a starting point. The plan is to publish more in-depth assessments of several of the stakeholder groups assessed and encourage others to do likewise. Several of the issues reported here will be part of the deliberations at the REWARD/EQUATOR meeting. The meeting will be a central point for groups such as funders, regulators, journals, academic institutions, and researchers, to help to increase the value of the enormous investments made in biomedical research. Everyone is responsible for helping to ensure that all research is planned, conducted, and reported to such high standards that the fi ndings are of value to all. Everyone deserves a guarantee of reliable evidence resulting from the global research endeavours.
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